Rexin-G is under clinical development by Epeius Biotechnologies and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rexin-G’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rexin-G overview

Rexin-G is under development for the treatment of chondrosarcoma, chordoma, sarcoma, pancreatic cancer, osteosarcoma, soft tissue sarcoma and Coronavirus Disease 2019 (COVID-19) associated with pneumonia and acute respiratory distres syndrome. It was under development for the treatments of advanced metastatic breast cancer and metastatic cancer. Rexin-G is a sophisticated gene delivery vehicle (vector). It is a tumor-targeted nanoparticle that is programmed to deliver a tumor-killing designer gene precisely where it is needed most. It is a genetic medicine. It is highly active against a broad spectrum of chemo-resistant tumor types. It causes tumor shrinkage in patients suffering from metastatic cancer, without causing dose-limiting toxicity or organ damage. It is a biological agent directed towards tumors that have spread throughout the body. The drug candidate is administered intravenously. The combination of Rexin-G and Reximmune-C was under investigation for the treatment of cancer.

Epeius Biotechnologies overview

Epeius Biotechnologies (Epeius) is a biopharmaceutical company, based in the US. The company operates through drug manufacturing and delivery. It develops therapeutic and drug delivery system for the treatment of cancer. The company’s pipeline includes Rexin-G, a tumor targeted injectable genetic medicine for the treatment of primary and metastatic cancer and Reximmune-C a cancer vaccine. Its targeted drug Delivery System works by injecting stealth nanoparticles directly into a vein so that the therapeutic genes can be delivered to selected cancerous lesions without affecting normal cells and healthy tissues. The company was incorporated in the year, 2000. Epeius is headquartered in San Marino, California, the US.

For a complete picture of Rexin-G’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.